AU2011240752B2 - Methods and compositions for inhibition of Treg cells - Google Patents

Methods and compositions for inhibition of Treg cells Download PDF

Info

Publication number
AU2011240752B2
AU2011240752B2 AU2011240752A AU2011240752A AU2011240752B2 AU 2011240752 B2 AU2011240752 B2 AU 2011240752B2 AU 2011240752 A AU2011240752 A AU 2011240752A AU 2011240752 A AU2011240752 A AU 2011240752A AU 2011240752 B2 AU2011240752 B2 AU 2011240752B2
Authority
AU
Australia
Prior art keywords
cells
patient
disease
emth
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2011240752A
Other languages
English (en)
Other versions
AU2011240752A1 (en
Inventor
Michael Har-Noy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunovative Therapies Ltd
Original Assignee
Immunovative Therapies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunovative Therapies Ltd filed Critical Immunovative Therapies Ltd
Publication of AU2011240752A1 publication Critical patent/AU2011240752A1/en
Application granted granted Critical
Publication of AU2011240752B2 publication Critical patent/AU2011240752B2/en
Priority to AU2016231642A priority Critical patent/AU2016231642B2/en
Priority to AU2018204834A priority patent/AU2018204834B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4262—Heat shock proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1114—T cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2011240752A 2010-04-13 2011-04-12 Methods and compositions for inhibition of Treg cells Active AU2011240752B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2016231642A AU2016231642B2 (en) 2010-04-13 2016-09-26 Methods and compositions for inhibition of treg cells
AU2018204834A AU2018204834B2 (en) 2010-04-13 2018-07-03 METHODS AND COMPOSITIONS FOR INHIBITION OF Treg CELLS

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32355710P 2010-04-13 2010-04-13
US61/323,557 2010-04-13
PCT/US2011/032090 WO2011130249A2 (en) 2010-04-13 2011-04-12 Methods and compositions for inhibition of treg cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2016231642A Division AU2016231642B2 (en) 2010-04-13 2016-09-26 Methods and compositions for inhibition of treg cells

Publications (2)

Publication Number Publication Date
AU2011240752A1 AU2011240752A1 (en) 2012-11-08
AU2011240752B2 true AU2011240752B2 (en) 2016-07-28

Family

ID=44761077

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2011240752A Active AU2011240752B2 (en) 2010-04-13 2011-04-12 Methods and compositions for inhibition of Treg cells
AU2016231642A Active AU2016231642B2 (en) 2010-04-13 2016-09-26 Methods and compositions for inhibition of treg cells
AU2018204834A Active AU2018204834B2 (en) 2010-04-13 2018-07-03 METHODS AND COMPOSITIONS FOR INHIBITION OF Treg CELLS

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2016231642A Active AU2016231642B2 (en) 2010-04-13 2016-09-26 Methods and compositions for inhibition of treg cells
AU2018204834A Active AU2018204834B2 (en) 2010-04-13 2018-07-03 METHODS AND COMPOSITIONS FOR INHIBITION OF Treg CELLS

Country Status (12)

Country Link
US (2) US20110250173A1 (enExample)
EP (1) EP2558123B1 (enExample)
JP (2) JP6294666B2 (enExample)
KR (3) KR20200063262A (enExample)
CN (1) CN103002915B (enExample)
AU (3) AU2011240752B2 (enExample)
BR (1) BR112012026007A2 (enExample)
CA (1) CA2796053A1 (enExample)
IL (2) IL275017B2 (enExample)
PH (1) PH12012502233A1 (enExample)
SG (2) SG10201509539UA (enExample)
WO (1) WO2011130249A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011240752B2 (en) * 2010-04-13 2016-07-28 Immunovative Therapies, Ltd. Methods and compositions for inhibition of Treg cells
CA2936086C (en) 2014-01-08 2024-02-27 Immunovative Therapies, Ltd. Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome
TWI714529B (zh) * 2015-05-20 2021-01-01 以色列商梵提夫免疫療法公司 人類免疫缺乏病毒/後天性免疫缺乏症候群之治療
US11123404B2 (en) * 2016-01-07 2021-09-21 B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University Methods for generating immunotolerant responses
JP7002769B2 (ja) * 2016-09-16 2022-02-04 ベイラー カレッジ オブ メディスン ウイルス特異的ｔ細胞の活性化および拡大のためのプラットフォーム
KR102568343B1 (ko) 2020-01-10 2023-08-22 이뮤노바이옴 주식회사 신규한 락토바실러스 플란타룸(Lactobacillus plantarum) 균주, 균주 유래 다당체 및 이의 용도
GB202007321D0 (en) * 2020-05-18 2020-07-01 Inst De Medicina Molecular Joaeo Lobo Antunes T cells

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030134415A1 (en) * 2001-09-19 2003-07-17 Gruenberg Micheal L. Th1 cell adoptive immunotherapy
US20040228848A1 (en) * 2003-05-13 2004-11-18 Michael Har-Noy Allogeneic cell therapy: mirror effect
US20080112963A1 (en) * 2006-11-13 2008-05-15 Immunovative Therapies, Ltd. Ablative immunotherapy
WO2009135199A2 (en) * 2008-05-02 2009-11-05 Immunovative Therapies, Ltd. Vaccine compositions and methods
US20100086561A1 (en) * 2008-10-01 2010-04-08 Immunovative Therapies Ltd. Th1 vaccination priming for active immunotherapy

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837251A (en) 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
KR100731820B1 (ko) * 1998-10-05 2007-06-25 파멕사 에이/에스 치료적 백신화를 위한 새로운 방법
US6797480B1 (en) 1998-10-05 2004-09-28 University Of Connecticut Health Center Purification of heat shock/stress protein cell surface receptors and their use as immunotherapeutic agents
US7541184B2 (en) * 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US6875849B2 (en) 2001-05-01 2005-04-05 Arizona Board Of Regents Of Behalf Of The University Of Arizona Methods of recovering chaperone proteins and complexes thereof
EP1447092A4 (en) * 2001-09-28 2007-07-11 Haruo Sugiyama METHODS OF INDUCING ANTIGEN-SPECIFIC T CELLS
US7402431B2 (en) 2004-03-01 2008-07-22 Immunovative Therapies, Ltd. T-cell therapy formulation
US20110142887A1 (en) * 2009-12-15 2011-06-16 Immunovative Therapies Ltd. Methods and compositions for liquidation of tumors
US20080267964A1 (en) * 2005-02-17 2008-10-30 Masaki Terabe Synergistic Effect of Tgf-Beta Blockade and Immunogenic Agents on Tumors
WO2007067683A2 (en) * 2005-12-08 2007-06-14 University Of Louisville Research Foundation, Inc. Methods and compositions for expanding t regulatory cells
CA2649290C (en) * 2006-04-13 2017-04-04 Immunovative Therapies, Ltd. Allogeneic cell therapy for treatment of opportunistic infection
US7972594B2 (en) * 2006-11-13 2011-07-05 Immunovative Therapies Ltd. Ablative immunotherapy
WO2008126940A1 (ja) * 2007-04-10 2008-10-23 The University Of Tokyo 新規ｔ細胞
EP2141245A1 (en) * 2008-07-03 2010-01-06 Ivana Türbachova DNA methylation analysis of regulatory T cells through DNA-methylation analysis of the TSDR region of the gene foxP3
AU2011240752B2 (en) * 2010-04-13 2016-07-28 Immunovative Therapies, Ltd. Methods and compositions for inhibition of Treg cells
RS61406B1 (sr) * 2014-06-06 2021-03-31 Bluebird Bio Inc Poboljšane kompozicije t ćelija

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030134415A1 (en) * 2001-09-19 2003-07-17 Gruenberg Micheal L. Th1 cell adoptive immunotherapy
US20040228848A1 (en) * 2003-05-13 2004-11-18 Michael Har-Noy Allogeneic cell therapy: mirror effect
US20080112963A1 (en) * 2006-11-13 2008-05-15 Immunovative Therapies, Ltd. Ablative immunotherapy
WO2009135199A2 (en) * 2008-05-02 2009-11-05 Immunovative Therapies, Ltd. Vaccine compositions and methods
US20100086561A1 (en) * 2008-10-01 2010-04-08 Immunovative Therapies Ltd. Th1 vaccination priming for active immunotherapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HAR-NOY M, et al., Leukemia Research, (2009), Vol 33, pp 525-538. *
SOMERSON S, et al., J Immunol, (2001), Vol 167, pp 4844-4825. *

Also Published As

Publication number Publication date
JP6294666B2 (ja) 2018-03-14
AU2016231642A1 (en) 2016-10-27
JP2016155851A (ja) 2016-09-01
EP2558123A4 (en) 2014-03-19
CN103002915A (zh) 2013-03-27
SG10201509539UA (en) 2015-12-30
KR20180123183A (ko) 2018-11-14
KR102117350B1 (ko) 2020-06-02
AU2018204834B2 (en) 2020-02-06
US20110250173A1 (en) 2011-10-13
EP2558123C0 (en) 2023-08-09
BR112012026007A2 (pt) 2016-06-28
IL275017B2 (en) 2024-07-01
WO2011130249A3 (en) 2012-03-08
EP2558123B1 (en) 2023-08-09
SG184819A1 (en) 2012-11-29
EP2558123A2 (en) 2013-02-20
CN103002915B (zh) 2015-09-23
PH12012502233A1 (en) 2022-10-05
IL275017A (en) 2020-07-30
US20160361404A1 (en) 2016-12-15
KR20130060188A (ko) 2013-06-07
CA2796053A1 (en) 2011-10-20
AU2018204834A1 (en) 2018-08-02
HK1184362A1 (en) 2014-01-24
WO2011130249A2 (en) 2011-10-20
KR20200063262A (ko) 2020-06-04
IL275017B1 (en) 2024-03-01
IL222343B (en) 2020-06-30
IL222343A0 (en) 2012-12-31
AU2016231642B2 (en) 2018-04-05
JP2013523886A (ja) 2013-06-17
AU2011240752A1 (en) 2012-11-08

Similar Documents

Publication Publication Date Title
AU2018204834B2 (en) METHODS AND COMPOSITIONS FOR INHIBITION OF Treg CELLS
Liu et al. Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine
Sabado et al. Dendritic cell immunotherapy
US20120128656A1 (en) Vaccine compositions and methods
JP2018531022A (ja) 改変ヒト初代血液樹状細胞株を生成するための方法
JP2018531022A6 (ja) 改変ヒト初代血液樹状細胞株を生成するための方法
Schäfer et al. Innate immune cells for immunotherapy of autoimmune and cancer disorders
Janikashvili et al. Allogeneic effector/memory Th-1 cells impair FoxP3+ regulatory T lymphocytes and synergize with chaperone-rich cell lysate vaccine to treat leukemia
Subrahmanyam et al. Natural killer T cell based Immunotherapy
Ramírez et al. Impact of T cell selection methods in the success of clinical adoptive immunotherapy
HK1184362B (en) Methods and compositions for inhibition of treg cells
ES2673321T3 (es) Método para la maduración in vitro de células dendríticas
Bransi et al. Rational combination of immunotherapies with clinical efficacy in mice with advanced cancer
Li Adoptive Cell Therapy using CD4 T Helper 1-like and CD8 Cytotoxic T Lymphocytes in a Mouse Model of Melanoma
WO2024215831A2 (en) Xenogeneic antigen presenting cells and uses thereof
Zhang Tolerogenic CD4⁻ 8⁻ Dendritic Cells and their Conversion into Immunogenic Ones via TLR9 Signaling
Harris Modulating self-reactive immune responses in auto-and tumor-immunity
Grant Two Heads Are Better Than One: The Combination of Dendritic Cells & B Cells Yields An Improved T Cell Response Over Dendritic Cells Alone When Presenting Tumour Lysate Antigens
Lerret DNA vaccination combined with low-dose total body irradiation induces long-term breast tumor regression
Liu NanoAPC deliver antigen, IL-2 and co-stimulatory molecules to antigen specific T cells and activate viral specific T cells in chronic infections

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)